Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07104565 · ClinicalTrials.gov registry record · Phase 2
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
A Phase 2 study of Immune Thrombocytopenia, sponsored by Incyte Corporation.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 20
- Study locations
NCT07104565: Recruiting Phase 2 study of Immune Thrombocytopenia, sponsored by Incyte Corporation.
NCT07104565 is a Phase 2 study of Immune Thrombocytopenia that is actively recruiting participants, run by Incyte Corporation. The registered enrollment target is 56 participants, below the 114-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07104565, a Phase 2 study of Immune Thrombocytopenia, is actively recruiting participants, sponsored by Incyte Corporation.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
Primary Outcome
Defined as any adverse event, either reported for the first time or worsening of a pre-existing event after the first dose of study drug up to 90 days after the last dose of study drug.
Conditions Studied
Interventions
- DRUG INCA000585
Study Locations (20)
Other
- Chu Angers - Hôpital Hôtel Dieu - Angers
- Chu Caen - Hôpital de La Côte de Nacre - Caen
- Hôpital Henri Mondor - Créteil
- Chu Dijon - Hopital Du Bocage - Dijon
Victoria
- Box Hill Hospital - Box Hill
- Monash Medical Centre Clayton - Clayton
- The Alfred Hospital - Melbourne
Queensland
- Townsville University Hospital - Douglas
- Princess Alexandra Hospital Australia - Woolloongabba
Arizona
- Palo Verde Cancer Specialists Palo Verde Hematology Oncology, Ltd Glendale - Glendale
California
- Usc Norris Comprehensive Cancer Center - Los Angeles
Colorado
- Rocky Mountain Cancer Centers - Lone Tree
Connecticut
- Yale University School of Medicine - New Haven
Florida
- Gnp Research - Cooper City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2025-12-29 |
| Est. Completion | 2028-03-09 |
| Phase | Phase 2 |
What NCT07104565 shows while recruiting
NCT07104565 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 114-participant average among 6 other Immune Thrombocytopenia trials with a reported enrollment target (51% lower).
The record links to 1 condition, with Immune Thrombocytopenia appearing as the primary indexed condition, and to 1 intervention - of which INCA000585 is the first listed.
NCT07104565 names 20 study sites across 14 states, led by Other, Victoria, Queensland.
Frequently Asked Questions
What is clinical trial NCT07104565 about?
NCT07104565 is a clinical study titled "Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders". This study will evaluate the safety and efficacy of tafasitamab in adult participants with primary autoimmune blood cell disorders.
What is the current status of trial NCT07104565?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2025-12-29. Estimated completion is 2028-03-09.
What conditions does trial NCT07104565 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia.
What interventions are being tested in trial NCT07104565?
The interventions under investigation include: INCA000585 (DRUG).
Who is sponsoring clinical trial NCT07104565?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07104565 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cognitive Dysfunction in Chronic and Persistent Immune Thrombocytopenia
RECRUITING
-
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
RECRUITING · Phase 3
-
An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Rilzabrutinib in Adults and Adolescents With Persistent or Chronic Immune Thrombocytopenia (ITP)
ACTIVE NOT RECRUITING · Phase 3
-
Safety and Treatment Satisfaction in Adults With Chronic ITP After Switching to Avatrombopag From Eltrombopag or Romiplostim
COMPLETED · Phase 4
-
Long-term Study of Romiplostim in Thrombocytopenic Pediatric Patients With Immune Thrombocytopenia (ITP)
COMPLETED · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI